12/10/2025
December is Crohn’s & Colitis Awareness Month 💜
A reminder of how inflammatory bowel disease intersects with cancer risk and cancer care.
For oncology APPs, several key considerations stand out:
🔍 Elevated Colorectal Cancer Risk
Long-standing Crohn’s disease and ulcerative colitis significantly increase the risk of colorectal cancer. These patients benefit from risk-stratified surveillance, earlier colonoscopy intervals, and multidisciplinary management—especially when symptoms evolve.
⚡ IBD & Immunotherapy
Patients with pre-existing IBD may face a higher incidence of immune checkpoint inhibitor–related colitis, which can be severe. Early recognition of flare vs. ICI-toxicity, prompt stool studies, timely steroids/biologics when indicated, and early GI involvement are critical to safe treatment.
💡 The APP Role
APPs are central to identifying red flags, managing chronic symptoms amid cancer therapy, counseling on surveillance, and coordinating care across oncology, GI, surgery, and primary care. Our vigilance directly improves safety and outcomes for this complex population.